190 related articles for article (PubMed ID: 37099131)
1. The prognostic value of [
Sachpekidis C; Weru V; Kopp-Schneider A; Hassel JC; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2699-2714. PubMed ID: 37099131
[TBL] [Abstract][Full Text] [Related]
2. Interim [
Sachpekidis C; Kopp-Schneider A; Pan L; Papamichail D; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1932-1943. PubMed ID: 33336264
[TBL] [Abstract][Full Text] [Related]
3. Predictive value and accuracy of [
Ayati N; Jamshidi-Araghi Z; Hoellwerth M; Schweighofer-Zwink G; Hitzl W; Koelblinger P; Pirich C; Beheshti M
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2715-2726. PubMed ID: 37140669
[TBL] [Abstract][Full Text] [Related]
4. The role of interim
Sachpekidis C; Anwar H; Winkler J; Kopp-Schneider A; Larribere L; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1289-1296. PubMed ID: 29478079
[TBL] [Abstract][Full Text] [Related]
5. Can physiologic colonic [
Sachpekidis C; Stein-Thoeringer CK; Kopp-Schneider A; Weru V; Dimitrakopoulou-Strauss A; Hassel JC
Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3709-3722. PubMed ID: 37452874
[TBL] [Abstract][Full Text] [Related]
6. Assessment of early metabolic progression in melanoma patients under immunotherapy: an
Sachpekidis C; Kopp-Schneider A; Hassel JC; Dimitrakopoulou-Strauss A
EJNMMI Res; 2021 Sep; 11(1):89. PubMed ID: 34495433
[TBL] [Abstract][Full Text] [Related]
7.
Ito K; Teng R; Schöder H; Humm JL; Ni A; Michaud L; Nakajima R; Yamashita R; Wolchok JD; Weber WA
J Nucl Med; 2019 Mar; 60(3):335-341. PubMed ID: 30413661
[TBL] [Abstract][Full Text] [Related]
8. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using
Kitajima K; Watabe T; Nakajo M; Ishibashi M; Daisaki H; Soeda F; Tanemura A; Kanekura T; Yamazaki N; Ito K
Jpn J Radiol; 2022 Jan; 40(1):75-85. PubMed ID: 34287739
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study.
Sachpekidis C; Larribere L; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A; Hassel JC
Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):386-96. PubMed ID: 25359635
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of total metabolic tumour volume and therapy-response assessment by [
Annovazzi A; Ferraresi V; Rea S; Russillo M; Renna D; Carpano S; Sciuto R
Eur Radiol; 2022 May; 32(5):3398-3407. PubMed ID: 34779873
[TBL] [Abstract][Full Text] [Related]
11. Assessing immune organs on
Prigent K; Lasnon C; Ezine E; Janson M; Coudrais N; Joly E; Césaire L; Stefan A; Depontville M; Aide N
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2573-2585. PubMed ID: 33432374
[TBL] [Abstract][Full Text] [Related]
12. The utility of
Kitajima K; Kawanaka Y; Komoto H; Minami T; Yokoi T; Kuribayashi K; Kijima T; Nakamura A; Hashimoto M; Kondo N; Hasegawa S; Yamakado K
Hell J Nucl Med; 2021; 24(3):186-198. PubMed ID: 34901959
[TBL] [Abstract][Full Text] [Related]
13. Response evaluation after immunotherapy in NSCLC: Early response assessment using FDG PET/CT.
Park S; Lee Y; Kim TS; Kim SK; Han JY
Medicine (Baltimore); 2020 Dec; 99(51):e23815. PubMed ID: 33371161
[TBL] [Abstract][Full Text] [Related]
14. FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST.
Depardon E; Kanoun S; Humbert O; Bertaut A; Riedinger JM; Tal I; Vrigneaud JM; Lasserre M; Toubeau M; Berriolo-Riedinger A; Dygai-Cochet I; Fumoleau P; Brunotte F; Cochet A
PLoS One; 2018; 13(7):e0199529. PubMed ID: 30011328
[TBL] [Abstract][Full Text] [Related]
15. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
Skougaard K; Nielsen D; Jensen BV; Hendel HW
J Nucl Med; 2013 Jul; 54(7):1026-31. PubMed ID: 23572497
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal studies of the
Sachpekidis C; Anwar H; Winkler JK; Kopp-Schneider A; Larribere L; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
Cancer Immunol Immunother; 2018 Aug; 67(8):1261-1270. PubMed ID: 29872898
[TBL] [Abstract][Full Text] [Related]
17. The value of
Ayati N; Sadeghi R; Kiamanesh Z; Lee ST; Zakavi SR; Scott AM
Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):428-448. PubMed ID: 32728798
[TBL] [Abstract][Full Text] [Related]
18. Comparison of prognostic value of different metabolic response criteria determined by PET/CT in patients with metastatic breast cancer under CDK 4/6 inhibitor treatment.
Önner H; Eren OÖ; Körez MK; Yilmaz F; Kara Gedik G
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2023; 42(5):319-324. PubMed ID: 37030597
[TBL] [Abstract][Full Text] [Related]
19. Absolute number of new lesions on
Anwar H; Sachpekidis C; Winkler J; Kopp-Schneider A; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):376-383. PubMed ID: 29124281
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy.
Nakamoto R; Zaba LC; Rosenberg J; Reddy SA; Nobashi TW; Davidzon G; Aparici CM; Nguyen J; Moradi F; Iagaru A; Franc BL
Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2787-2795. PubMed ID: 32296882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
